Merck chief executive Karl-Ludwig Kley to step down in April
pharmafile | March 9, 2016 | Appointment | Medical Communications, Research and Development | Denreon, Karl-Ludwig Kley, Merck, karl ludwig kley
It has been announced that Karl-Ludwig Kley, chief executive officer at Merck, will step down from his position at the end of April to join German energy company, EON.
Kley has been at the helm of the German pharma company for almost nine years. While he hasn’t overseen any new medicines launched during that time, Kley has made significant efforts to diversify Merck’s offering in this time period, including last year’s acquisition of Sigma Alridch which was the largest in Merck’s history. This acquisition led to a rise in Q4 profits, which were announced just yesterday (Tuesday 8th March).
Kley previously held positions as chief financial officer at airline Lufthansa as well as executive roles with Bayer. His new role will see him replace Werner Wenning as chairman of the supervisory board of EON, and will take the position after the company’s annual general meeting on June 8.
Related Content
FDA approves Merck’s Capvaxive for prevention of pneumococcal disease
Merck, known as MSD outside of the US and Canada, has announced that the US …
Merck to acquire EyeBio for an upfront $1.3bn
Merck, known as MSD outside of the US and Canada, and EyeBiotech Limited, have announced …
Merck shares data from phase 3 trial of Keytruda for TNBC treatment
Merck, known as MSD outside of the US and Canada, has announced results from the …